A new letter from the House Judiciary Committee shows that the panel is seeking information from Pfizer (PFE) and from a former Pfizer scientist, Philip Dormitzer, who alleges that he was part of an effort to “deliberately slow down” sharing results of the COVID vaccine in 2020 until after that year’s presidential election, reported The Wall Street Journal’s Annie Linskey and Josh Dawsey.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Mixed options sentiment in Pfizer (PFE), with shares up $0.33 (+1.48%) near $22.34
- Pfizer’s Hold Rating: Balancing Policy Uncertainties and Long-Term Growth Prospects
- U.S. biotech companies debate relocating trials outside U.S., Reuters reports
- Terns Pharmaceuticals price target lowered to $15 from $26 at BMO Capital
- Trump’s drug-price crackdown may lead to minor concessions, WSJ reports